bundle-ibrance75-100-125
type: Bundle
node role: treeRoot
id:
  v: bundle-ibrance75-100-125
meta:
  version id:
    v: 1
  last updated:
    v: 2022-09-08T00:00:00Z
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi
    l: Bundle-uv-epi
identifier:
  system:
    v: https://www.fda.gov/
    l: www.fda.gov
  value:
    v: ibrance
type:
  v: document
timestamp:
  v: 2022-09-08T00:00:00Z
entry:
  full url:
    v: Composition/compositionusen
    l: compositionusen
  resource: compositionusen
entry:
  full url:
    v: Organization/UORG1
    l: UORG1
  resource: UORG1
entry:
  full url:
    v: Organization/UORG2
    l: UORG2
  resource: UORG2
entry:
  full url:
    v: Organization/UORG3
    l: UORG3
  resource: UORG3
entry:
  full url:
    v: Organization/UORG4
    l: UORG4
  resource: UORG4
entry:
  full url:
    v: Organization/UORG5
    l: UORG5
  resource: UORG5
entry:
  full url:
    v: Ingredient/UUID-CROSPOVIDONE
    l: UUID-CROSPOVIDONE
  resource: UUID-CROSPOVIDONE
entry:
  full url:
    v: Ingredient/UUID-FDCBLUE2
    l: UUID-FDCBLUE2
  resource: UUID-FDCBLUE2
entry:
  full url:
    v: Ingredient/UUID-FERRIC-OXIDE-RED
    l: UUID-FERRIC-OXIDE-RED
  resource: UUID-FERRIC-OXIDE-RED
entry:
  full url:
    v: Ingredient/UUID-FERRIC-OXIDE-YELLOW
    l: UUID-FERRIC-OXIDE-YELLOW
  resource: UUID-FERRIC-OXIDE-YELLOW
entry:
  full url:
    v: Ingredient/UUID-HYPROMELLOSE
    l: UUID-HYPROMELLOSE
  resource: UUID-HYPROMELLOSE
entry:
  full url:
    v: Ingredient/UUID-MAGNESIUM-STEARATE
    l: UUID-MAGNESIUM-STEARATE
  resource: UUID-MAGNESIUM-STEARATE
entry:
  full url:
    v: Ingredient/UUID-MICROCRYSTALLINE-CELLULOSE
    l: UUID-MICROCRYSTALLINE-CELLULOSE
  resource: UUID-MICROCRYSTALLINE-CELLULOSE
entry:
  full url:
    v: Ingredient/palbociclib75
    l: palbociclib75
  resource: palbociclib75
entry:
  full url:
    v: Ingredient/UUID-PALBOCICLIB100
    l: UUID-PALBOCICLIB100
  resource: UUID-PALBOCICLIB100
entry:
  full url:
    v: Ingredient/UUID-PALBOCICLIB125
    l: UUID-PALBOCICLIB125
  resource: UUID-PALBOCICLIB125
entry:
  full url:
    v: Ingredient/UUID-SILICON-DIOXIDE
    l: UUID-SILICON-DIOXIDE
  resource: UUID-SILICON-DIOXIDE
entry:
  full url:
    v: Ingredient/UUID-SUCCINIC-ACID
    l: UUID-SUCCINIC-ACID
  resource: UUID-SUCCINIC-ACID
entry:
  full url:
    v: Ingredient/UUID-TITANIUM-DIOXIDE
    l: UUID-TITANIUM-DIOXIDE
  resource: UUID-TITANIUM-DIOXIDE
entry:
  full url:
    v: Ingredient/UUID-TRIACETIN
    l: UUID-TRIACETIN
  resource: UUID-TRIACETIN
entry:
  full url:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
    l: UUID-MID-PALBOCICLIB75
  resource: UUID-MID-PALBOCICLIB75
entry:
  full url:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
    l: UUID-MID-PALBOCICLIB75
  resource: UUID-MID-PALBOCICLIB75
entry:
  full url:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
    l: UUID-MID-PALBOCICLIB125
  resource: UUID-MID-PALBOCICLIB125
entry:
  full url:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
    l: UUID-MPD-PALBOCICLIB75
  resource: UUID-MPD-PALBOCICLIB75
entry:
  full url:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
    l: UUID-MPD-PALBOCICLIB100
  resource: UUID-MPD-PALBOCICLIB100
entry:
  full url:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
    l: UUID-MPD-PALBOCICLIB125
  resource: UUID-MPD-PALBOCICLIB125
entry:
  full url:
    v: AdministrableProductDefinition/UUID-APD-PALBOCICLIB75
    l: UUID-APD-PALBOCICLIB75
  resource: UUID-APD-PALBOCICLIB75
entry:
  full url:
    v: AdministrableProductDefinition/UUID-APD-PALBOCICLIB100
    l: UUID-APD-PALBOCICLIB100
  resource: UUID-APD-PALBOCICLIB100
entry:
  full url:
    v: AdministrableProductDefinition/UUID-APD-PALBOCICLIB125
    l: UUID-APD-PALBOCICLIB125
  resource: UUID-APD-PALBOCICLIB125
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB75-TAB-MONTH
    l: UUID-PPD-PALBOCICLIB75-TAB-MONTH
  resource: UUID-PPD-PALBOCICLIB75-TAB-MONTH
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB75-TAB-WEEK
    l: UUID-PPD-PALBOCICLIB75-TAB-WEEK
  resource: UUID-PPD-PALBOCICLIB75-TAB-WEEK
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB100-TAB-MONTH
    l: UUID-PPD-PALBOCICLIB100-TAB-MONTH
  resource: UUID-PPD-PALBOCICLIB100-TAB-MONTH
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB100-TAB-WEEK
    l: UUID-PPD-PALBOCICLIB100-TAB-WEEK
  resource: UUID-PPD-PALBOCICLIB100-TAB-WEEK
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB125-TAB-MONTH
    l: UUID-PPD-PALBOCICLIB125-TAB-MONTH
  resource: UUID-PPD-PALBOCICLIB125-TAB-MONTH
entry:
  full url:
    v: PackagedProductDefinition/UUID-PPD-PALBOCICLIB125-TAB-WEEK
    l: UUID-PPD-PALBOCICLIB125-TAB-WEEK
  resource: UUID-PPD-PALBOCICLIB125-TAB-WEEK
entry:
  full url:
    v: RegulatedAuthorization/UUID-RA-PALBOCICLIB75
    l: UUID-RA-PALBOCICLIB75
  resource: UUID-RA-PALBOCICLIB75

compositionusen
type: Composition
id:
  v: compositionusen
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi
    l: Composition-uv-epi
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Composition compositionusen Language: en Profile: Composition (ePI) org/fhir/dummyValidationReference: UUID-IBRANCE-05 org/fhir/dummyValidationReference: UUID-IBRANCE-06 org/fhir/dummyValidationReference: UUID-IBRANCE-07 org/fhir/dummyValidationReference: UUID-IBRANCE-08 org/fhir/dummyValidationReference: UUID-IBRANCE-09 org/fhir/dummyValidationReference: UUID-IBRANCE-10 org/fhir/dummyValidationReference: UUID-IBRANCE-11 org/fhir/dummyValidationReference: UUID-IBRANCE-12 org/fhir/dummyValidationReference: UUID-IBRANCE-13 identifier: https://www.fda.gov//0d69fdcb-33cf-407f-8209-a6529856ab4f status: Final type: HUMAN PRESCRIPTION LABEL date: 2023-09-08 00:00:00+0000 author: Organization Pfizer Laboratories Div Pfizer Inc title: Ibrance (palbociclib) tablets - THIS DOCUMENT IS FOR TESTING PURPOSES ONLY. Generated Narrative: Binary #UUID-IBRANCE-05 contentType: image/jpeg data: (base64 data - 16,641 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-06 contentType: image/jpeg data: (base64 data - 16,640 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-07 contentType: image/jpeg data: (base64 data - 133,000 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-08 contentType: image/jpeg data: (base64 data - 180,920 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-09 contentType: image/jpeg data: (base64 data - 469,792 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-10 contentType: image/jpeg data: (base64 data - 190,380 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-11 contentType: image/jpeg data: (base64 data - 480,396 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-12 contentType: image/jpeg data: (base64 data - 193,084 base64 chars) Generated Narrative: Binary #UUID-IBRANCE-13 contentType: image/jpeg data: (base64 data - 478,512 base64 chars)
contained: Binary
  id:
    v: UUID-IBRANCE-05
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-06
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-07
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-08
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-09
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-10
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-11
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-12
  content type:
    v: image/jpeg
contained: Binary
  id:
    v: UUID-IBRANCE-13
  content type:
    v: image/jpeg
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-05
    reference:
      v: UUID-IBRANCE-05
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-06
    reference:
      v: UUID-IBRANCE-06
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-07
    reference:
      v: UUID-IBRANCE-07
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-08
    reference:
      v: UUID-IBRANCE-08
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-09
    reference:
      v: UUID-IBRANCE-09
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-10
    reference:
      v: UUID-IBRANCE-10
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-11
    reference:
      v: UUID-IBRANCE-11
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-12
    reference:
      v: UUID-IBRANCE-12
extension:
  url:
    v: http://example.org/fhir/dummyValidationReference
    l: dummyValidationReference
  value: Reference
    l: UUID-IBRANCE-13
    reference:
      v: UUID-IBRANCE-13
identifier:
  system:
    v: https://www.fda.gov/
    l: www.fda.gov
status:
  v: final
type:
  coding: https://loinc.org/rdf/34391-3
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 34391-3
    display:
      v: HUMAN PRESCRIPTION LABEL
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
date:
  v: 2023-09-08T00:00:00Z
author:
  l: ORG1
  reference:
    v: Organization/ORG1
title:
  v: Ibrance (palbociclib) tablets - THIS DOCUMENT IS FOR TESTING PURPOSES ONLY.
section:
  id:
    v: UUID-COMPOSITION-PARENT-SECTION
  title:
    v: SPL PATIENT PACKAGE INSERT SECTION
  code:
    coding: https://loinc.org/rdf/42230-3
      system:
        v: http://loinc.org
        l: loinc.org
      code:
        v: 42230-3
      display:
        v: SPL PATIENT PACKAGE INSERT SECTION
  section:
    id:
      v: UUID-NESTED-SECTION-1
    title:
      v: PATIENT INFORMATION
    code:
      coding: https://loinc.org/rdf/42229-5
    text:
      status:
        v: generated
      div:
        v: IBRANCE ® (EYE-brans) (palbociclib) Tablets
  section:
    id:
      v: UUID-NESTED-SECTION-2
    title:
      v: What is the most important information I should know about IBRANCE?
    code:
      coding: https://loinc.org/rdf/42229-5
    text:
      status:
        v: generated
      div:
        v: IBRANCE may cause serious side effects, including: Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with IBRANCE, your healthcare provider may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills. Lung problems (pneumonitis). IBRANCE may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: chest pain cough with or without mucus trouble breathing or shortness of breath Your healthcare provider may interrupt or stop treatment with IBRANCE completely if your symptoms are severe. See "What are the possible side effects of IBRANCE?" for more information about side effects.

UORG1
type: Organization
id:
  v: ORG1
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization ORG1 Profile: Organization (ePI) identifier: urn:oid:1.3.6.1.4.1.519.1/134489525 active: true type: Non-Healthcare Business or Corporation name: Pfizer Laboratories Div Pfizer Inc
identifier:
  system:
    v: urn:oid:1.3.6.1.4.1.519.1
    l: 1.3.6.1.4.1.519.1
  value:
    v: 134489525
active:
  v: true
type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/organization-type
      l: organization-type
    code:
      v: bus
    display:
      v: Non-Healthcare Business or Corporation
name:
  v: Pfizer Laboratories Div Pfizer Inc

UORG2
type: Organization
id:
  v: ORG2
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization ORG2 Profile: Organization (ePI) identifier: urn:oid:1.3.6.1.4.1.519.1/985052076 active: true type: Non-Healthcare Business or Corporation name: Pfizer Ireland Pharmaceuticals
identifier:
  system:
    v: urn:oid:1.3.6.1.4.1.519.1
    l: 1.3.6.1.4.1.519.1
  value:
    v: 985052076
active:
  v: true
type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/organization-type
      l: organization-type
    code:
      v: bus
    display:
      v: Non-Healthcare Business or Corporation
name:
  v: Pfizer Ireland Pharmaceuticals

UORG3
type: Organization
id:
  v: ORG3
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization ORG3 Profile: Organization (ePI) identifier: urn:oid:1.3.6.1.4.1.519.1/341970073 active: true type: Non-Healthcare Business or Corporation name: Pfizer Manufacturing Deutschland GmbH
identifier:
  system:
    v: urn:oid:1.3.6.1.4.1.519.1
    l: 1.3.6.1.4.1.519.1
  value:
    v: 341970073
active:
  v: true
type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/organization-type
      l: organization-type
    code:
      v: bus
    display:
      v: Non-Healthcare Business or Corporation
name:
  v: Pfizer Manufacturing Deutschland GmbH

UORG4
type: Organization
id:
  v: ORG4
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization ORG4 Profile: Organization (ePI) identifier: urn:oid:1.3.6.1.4.1.519.1/936889401 active: true type: Non-Healthcare Business or Corporation name: Pfizer Asia Manufacturing Pte Ltd
identifier:
  system:
    v: urn:oid:1.3.6.1.4.1.519.1
    l: 1.3.6.1.4.1.519.1
  value:
    v: 936889401
active:
  v: true
type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/organization-type
      l: organization-type
    code:
      v: bus
    display:
      v: Non-Healthcare Business or Corporation
name:
  v: Pfizer Asia Manufacturing Pte Ltd

UORG5
type: Organization
id:
  v: ORG5
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi
    l: Organization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization ORG5 Profile: Organization (ePI) identifier: urn:oid:1.3.6.1.4.1.519.1/999999999999999 active: true type: Government name: Food and Drug Administration
identifier:
  system:
    v: urn:oid:1.3.6.1.4.1.519.1
    l: 1.3.6.1.4.1.519.1
  value:
    v: 999999999999999
active:
  v: true
type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/organization-type
      l: organization-type
    code:
      v: govt
    display:
      v: Government
name:
  v: Food and Drug Administration

UUID-CROSPOVIDONE
type: Ingredient
id:
  v: UUID-CROSPOVIDONE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-CROSPOVIDONE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/2S7830E561 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: inactive ingredient allergenicIndicator: true substance Codes - Concept * CROSPOVIDONE
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: 2S7830E561
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
allergenic indicator:
  v: true

UUID-FDCBLUE2
type: Ingredient
id:
  v: UUID-FDCBLUE2
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-FDCBLUE2 Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/L06K8R7DQK (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * FD&C BLUE NO. 2
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: L06K8R7DQK
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-FERRIC-OXIDE-RED
type: Ingredient
id:
  v: UUID-FERRIC-OXIDE-RED
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-FERRIC-OXIDE-RED Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/1K09F3G675 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * FERRIC OXIDE RED
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: 1K09F3G675
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-FERRIC-OXIDE-YELLOW
type: Ingredient
id:
  v: UUID-FERRIC-OXIDE-YELLOW
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-FERRIC-OXIDE-YELLOW Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/EX438O2MRT (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * FERRIC OXIDE YELLOW
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: EX438O2MRT
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-HYPROMELLOSE
type: Ingredient
id:
  v: UUID-HYPROMELLOSE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-HYPROMELLOSE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/0WZ8WG20P6 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * HYPROMELLOSE 2910 (6 MPA.S)
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: 0WZ8WG20P6
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-MAGNESIUM-STEARATE
type: Ingredient
id:
  v: UUID-MAGNESIUM-STEARATE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-MAGNESIUM-STEARATE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/70097M6I30 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: inactive ingredient allergenicIndicator: false substance Codes - Concept * MAGNESIUM STEARATE
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: 70097M6I30
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
allergenic indicator:
  v: false

UUID-MICROCRYSTALLINE-CELLULOSE
type: Ingredient
id:
  v: UUID-MICROCRYSTALLINE-CELLULOSE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-MICROCRYSTALLINE-CELLULOSE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/OP1R32D61U (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * MICROCRYSTALLINE CELLULOSE
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: OP1R32D61U
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

palbociclib75
type: Ingredient
id:
  v: palbociclib75
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient palbociclib75 Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/G9ZF61LE7G (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Active group: Kinase Inhibitor allergenicIndicator: false comment: PALBOCICLIB 75mg substance Codes - Concept * G9ZF61LE7G Strengths - Presentation[x] * 75 mg/1 1
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: G9ZF61LE7G
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: ACTIB
    display:
      v: active ingredient - basis of strength
  text:
    v: Active
group:
  coding:
    system:
      v: http://ncimeta.nci.nih.gov
      l: ncimeta.nci.nih.gov
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor
allergenic indicator:
  v: false
comment:
  v: PALBOCICLIB 75mg
substance:
  strength:
    presentation: Ratio

UUID-PALBOCICLIB100
type: Ingredient
id:
  v: UUID-PALBOCICLIB100
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-PALBOCICLIB100 Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/G9ZF61LE7G (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Active group: Kinase Inhibitor allergenicIndicator: false comment: PALBOCICLIB 100mg substance Codes - Concept * G9ZF61LE7G Strengths - Presentation[x] * 100 mg/1 1
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: G9ZF61LE7G
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: ACTIB
    display:
      v: active ingredient - basis of strength
  text:
    v: Active
group:
  coding:
    system:
      v: http://ncimeta.nci.nih.gov
      l: ncimeta.nci.nih.gov
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor
allergenic indicator:
  v: false
comment:
  v: PALBOCICLIB 100mg
substance:
  strength:
    presentation: Ratio

UUID-PALBOCICLIB125
type: Ingredient
id:
  v: UUID-PALBOCICLIB125
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-PALBOCICLIB125 Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/G9ZF61LE7G (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Active group: Kinase Inhibitor allergenicIndicator: false comment: PALBOCICLIB 125mg substance Codes - Concept * G9ZF61LE7G Strengths - Presentation[x] * 125 mg/1 1
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: G9ZF61LE7G
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: ACTIB
    display:
      v: active ingredient - basis of strength
  text:
    v: Active
group:
  coding:
    system:
      v: http://ncimeta.nci.nih.gov
      l: ncimeta.nci.nih.gov
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor
allergenic indicator:
  v: false
comment:
  v: PALBOCICLIB 125mg
substance:
  strength:
    presentation: Ratio

UUID-SILICON-DIOXIDE
type: Ingredient
id:
  v: UUID-SILICON-DIOXIDE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-SILICON-DIOXIDE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/ETJ7Z6XBU4 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * SILICON DIOXIDE
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: ETJ7Z6XBU4
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-SUCCINIC-ACID
type: Ingredient
id:
  v: UUID-SUCCINIC-ACID
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-SUCCINIC-ACID Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/AB6MNQ6J6L (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * SUCCINIC ACID
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: AB6MNQ6J6L
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-TITANIUM-DIOXIDE
type: Ingredient
id:
  v: UUID-TITANIUM-DIOXIDE
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-TITANIUM-DIOXIDE Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/15FIX9V2JP (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * 15FIX9V2JP
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: 15FIX9V2JP
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-TRIACETIN
type: Ingredient
id:
  v: UUID-TRIACETIN
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi
    l: Ingredient-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Ingredient UUID-TRIACETIN Profile: Ingredient (ePI) identifier: <a href="http://terminology.hl7.org/6.5.0/NamingSystem-UNII.html" title="A UNII is a non-proprietary, free, unique, unambiguous, nonsemantic, alphanumeric identifier based on a substance's molecular structure and/or descriptive information. UNII identifiers are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication.">Unique Ingredient Identifier (UNII)/XHX3C3X673 (use: official, ) status: Active for: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit role: Inactive allergenicIndicator: false substance Codes - Concept * TRIACETIN
identifier:
  use:
    v: official
  system:
    v: http://fdasis.nlm.nih.gov
    l: fdasis.nlm.nih.gov
  value:
    v: XHX3C3X673
status:
  v: active
for:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
for:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
for:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
role:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-RoleClass
      l: v3-RoleClass
    code:
      v: IACT
    display:
      v: inactive ingredient
  text:
    v: Inactive
allergenic indicator:
  v: false

UUID-MID-PALBOCICLIB75
type: ManufacturedItemDefinition
id:
  v: UUID-MID-PALBOCICLIB75
id:
  v: UUID-MID-PALBOCICLIB100
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi
    l: ManufacturedItemDefinition-uv-epi
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi
    l: ManufacturedItemDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ManufacturedItemDefinition UUID-MID-PALBOCICLIB75 Profile: ManufacturedItemDefinition (ePI) identifier: National drug codes/0069-0284 (use: official, ) status: Active manufacturedDoseForm: TABLET, FILM COATED unitOfPresentation: TABLET manufacturer: Organization Pfizer Ireland Pharmaceuticals Organization Pfizer Manufacturing Deutschland GmbH Organization Pfizer Asia Manufacturing Pte Ltd property type: COLOR value: PURPLE property type: SHAPE value: ROUND property type: SIZE value: 10 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;75
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ManufacturedItemDefinition UUID-MID-PALBOCICLIB100 Profile: ManufacturedItemDefinition (ePI) identifier: National drug codes/0069-0486 (use: official, ) status: Active manufacturedDoseForm: TABLET, FILM COATED unitOfPresentation: TABLET manufacturer: Organization Pfizer Ireland Pharmaceuticals Organization Pfizer Manufacturing Deutschland GmbH Organization Pfizer Asia Manufacturing Pte Ltd property type: COLOR value: GREEN property type: SHAPE value: OVAL property type: SIZE value: 15 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;100
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0284
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0486
status:
  v: active
status:
  v: active
manufactured dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
manufactured dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
  text:
    v: TABLET
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
  text:
    v: TABLET
manufacturer:
  l: ORG2
  reference:
    v: Organization/ORG2
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
manufacturer:
  l: ORG4
  reference:
    v: Organization/ORG4
manufacturer:
  l: ORG2
  reference:
    v: Organization/ORG2
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
manufacturer:
  l: ORG4
  reference:
    v: Organization/ORG4
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
    text:
      v: COLOR
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48327
      display:
        v: Purple
    text:
      v: PURPLE
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48557
      display:
        v: Structured Product Labeling Shape
    text:
      v: SHAPE
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48348
      display:
        v: Round
    text:
      v: ROUND
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLSIZE
    text:
      v: SIZE
  value: Quantity
    value:
      v: 10
    unit:
      v: millimeter
    system:
      v: https://unitsofmeasure.org
      l: unitsofmeasure.org
    code:
      v: mm
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLIMPRINT
  value: CodeableConcept
    text:
      v: Pfizer;PBC;75
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
    text:
      v: COLOR
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov

UUID-MID-PALBOCICLIB125
type: ManufacturedItemDefinition
id:
  v: UUID-MID-PALBOCICLIB125
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi
    l: ManufacturedItemDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ManufacturedItemDefinition UUID-MID-PALBOCICLIB125 Profile: ManufacturedItemDefinition (ePI) identifier: National drug codes/0069-0688 (use: official, ) status: Active manufacturedDoseForm: TABLET, FILM COATED unitOfPresentation: TABLET manufacturer: Organization Pfizer Ireland Pharmaceuticals Organization Pfizer Manufacturing Deutschland GmbH Organization Pfizer Asia Manufacturing Pte Ltd property type: COLOR value: PURPLE property type: SHAPE value: OVAL property type: SIZE value: 16 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;125
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0688
status:
  v: active
manufactured dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
  text:
    v: TABLET
manufacturer:
  l: ORG2
  reference:
    v: Organization/ORG2
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
manufacturer:
  l: ORG4
  reference:
    v: Organization/ORG4
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
    text:
      v: COLOR
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48327
      display:
        v: Purple
    text:
      v: PURPLE
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48557
      display:
        v: Structured Product Labeling Shape
    text:
      v: SHAPE
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48345
      display:
        v: Oval
    text:
      v: OVAL
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLSIZE
    text:
      v: SIZE
  value: Quantity
    value:
      v: 16
    unit:
      v: millimeter
    system:
      v: https://unitsofmeasure.org
      l: unitsofmeasure.org
    code:
      v: mm
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLIMPRINT
  value: CodeableConcept
    text:
      v: Pfizer;PBC;125

UUID-MPD-PALBOCICLIB75
type: MedicinalProductDefinition
id:
  v: UUID-MPD-PALBOCICLIB75
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi
    l: MedicinalProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicinalProductDefinition UUID-MPD-PALBOCICLIB75 Profile: MedicinalProductDefinition (ePI) identifier: National drug codes/0069-0284 (use: official, ) type: Approved for Human Use Product domain: Human version: 1 status: Active statusDate: 2020-03-30 00:00:00+0000 combinedPharmaceuticalDoseForm: TABLET, FILM COATED legalStatusOfSupply: Marketing Authorization classification: Kinase Inhibitor [EPC] MarketingStatuses - Status * Marketing Contacts - Contact * Organization Pfizer Laboratories Div Pfizer Inc name productName: IBRANCE® (palbociclib) tablets - 75 mg type: Proprietary Name Usages - Country Jurisdiction Language * United States of America United States of America English
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0284
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
domain:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C14225
    display:
      v: Human
version:
  v: 1
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
combined pharmaceutical dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
legal status of supply:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
classification:
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor [EPC]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175082
    display:
      v: Kinase Inhibitors [MoA]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000190114
    display:
      v: Cytochrome P450 3A Inhibitors [MoA]
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
contact:
  contact:
    l: ORG1
    reference:
      v: Organization/ORG1
name:
  product name:
    v: IBRANCE® (palbociclib) tablets - 75 mg
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C71898
      display:
        v: Proprietary Name

UUID-MPD-PALBOCICLIB100
type: MedicinalProductDefinition
id:
  v: UUID-MPD-PALBOCICLIB100
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi
    l: MedicinalProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicinalProductDefinition UUID-MPD-PALBOCICLIB100 Profile: MedicinalProductDefinition (ePI) identifier: National drug codes/0069-0486 (use: official, ) type: Approved for Human Use Product domain: Human version: 1 status: Active statusDate: 2020-03-30 00:00:00+0000 combinedPharmaceuticalDoseForm: TABLET, FILM COATED legalStatusOfSupply: Marketing Authorization classification: Kinase Inhibitor [EPC] MarketingStatuses - Status * Marketing Contacts - Contact * Organization Pfizer Laboratories Div Pfizer Inc name productName: IBRANCE® (palbociclib) tablets - 100 mg type: Proprietary Name Usages - Country Jurisdiction Language * United States of America United States of America English
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0486
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
domain:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C14225
    display:
      v: Human
version:
  v: 1
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
combined pharmaceutical dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
legal status of supply:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
classification:
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor [EPC]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175082
    display:
      v: Kinase Inhibitors [MoA]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000190114
    display:
      v: Cytochrome P450 3A Inhibitors [MoA]
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
contact:
  contact:
    l: ORG1
    reference:
      v: Organization/ORG1
name:
  product name:
    v: IBRANCE® (palbociclib) tablets - 100 mg
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C71898
      display:
        v: Proprietary Name

UUID-MPD-PALBOCICLIB125
type: MedicinalProductDefinition
id:
  v: UUID-MPD-PALBOCICLIB125
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi
    l: MedicinalProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicinalProductDefinition UUID-MPD-PALBOCICLIB125 Profile: MedicinalProductDefinition (ePI) identifier: National drug codes/0069-0688 (use: official, ) type: Approved for Human Use Product domain: Human version: 1 status: Active statusDate: 2020-03-30 00:00:00+0000 combinedPharmaceuticalDoseForm: TABLET, FILM COATED legalStatusOfSupply: Marketing Authorization classification: Kinase Inhibitor [EPC] MarketingStatuses - Status * Marketing Contacts - Contact * Organization Pfizer Laboratories Div Pfizer Inc name productName: IBRANCE® (palbociclib) tablets - 125 mg type: Proprietary Name Usages - Country Jurisdiction Language * United States of America United States of America English
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0688
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
domain:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C14225
    display:
      v: Human
version:
  v: 1
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
combined pharmaceutical dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
  text:
    v: TABLET, FILM COATED
legal status of supply:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
classification:
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175605
    display:
      v: Kinase Inhibitor [EPC]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000175082
    display:
      v: Kinase Inhibitors [MoA]
  coding:
    system:
      v: http://hl7.org/fhir/medrt
      l: medrt
    code:
      v: N0000190114
    display:
      v: Cytochrome P450 3A Inhibitors [MoA]
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
contact:
  contact:
    l: ORG1
    reference:
      v: Organization/ORG1
name:
  product name:
    v: IBRANCE® (palbociclib) tablets - 125 mg
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C71898
      display:
        v: Proprietary Name

UUID-APD-PALBOCICLIB75
type: AdministrableProductDefinition
id:
  v: UUID-APD-PALBOCICLIB75
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi
    l: AdministrableProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: AdministrableProductDefinition UUID-APD-PALBOCICLIB75 Profile: AdministrableProductDefinition (ePI) identifier: National drug codes/0069-0284 (use: official, ) status: Active formOf: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] administrableDoseForm: Film Coated Tablet Dosage Form unitOfPresentation: Tablet Dosing Unit producedFrom: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit property type: Structured Product Labeling Color value: Purple property type: Structured Product Labeling Shape value: Round property type: SPLSIZE value: 10 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;75 routeOfAdministration code: ORAL TargetSpecies - Code * HUMAN
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0284
status:
  v: active
form of:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
administrable dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
produced from:
  l: UUID-MID-PALBOCICLIB75
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48327
      display:
        v: Purple
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48557
      display:
        v: Structured Product Labeling Shape
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48348
      display:
        v: Round
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLSIZE
  value: Quantity
    value:
      v: 10
    unit:
      v: millimeter
    system:
      v: https://unitsofmeasure.org
      l: unitsofmeasure.org
    code:
      v: mm
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLIMPRINT
  value: CodeableConcept
    text:
      v: Pfizer;PBC;75
route of administration:
  code:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C38288
      display:
        v: Oral Route of Administration
    text:
      v: ORAL
  target species:
    code:
      text:
        v: HUMAN

UUID-APD-PALBOCICLIB100
type: AdministrableProductDefinition
id:
  v: UUID-APD-PALBOCICLIB100
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi
    l: AdministrableProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: AdministrableProductDefinition UUID-APD-PALBOCICLIB100 Profile: AdministrableProductDefinition (ePI) identifier: National drug codes/0069-0486 (use: official, ) status: Active formOf: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] administrableDoseForm: Film Coated Tablet Dosage Form unitOfPresentation: Tablet Dosing Unit producedFrom: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit property type: Structured Product Labeling Color value: Green property type: Structured Product Labeling Shape value: Oval property type: SIZE value: 15 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;100 routeOfAdministration code: ORAL TargetSpecies - Code * HUMAN
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0486
status:
  v: active
form of:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
administrable dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
produced from:
  l: UUID-MID-PALBOCICLIB100
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48329
      display:
        v: Green
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48557
      display:
        v: Structured Product Labeling Shape
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48345
      display:
        v: Oval
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLSIZE
    text:
      v: SIZE
  value: Quantity
    value:
      v: 15
    unit:
      v: millimeter
    system:
      v: https://unitsofmeasure.org
      l: unitsofmeasure.org
    code:
      v: mm
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLIMPRINT
  value: CodeableConcept
    text:
      v: Pfizer;PBC;100
route of administration:
  code:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C38288
      display:
        v: Oral Route of Administration
    text:
      v: ORAL
  target species:
    code:
      text:
        v: HUMAN

UUID-APD-PALBOCICLIB125
type: AdministrableProductDefinition
id:
  v: UUID-APD-PALBOCICLIB125
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi
    l: AdministrableProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: AdministrableProductDefinition UUID-APD-PALBOCICLIB125 Profile: AdministrableProductDefinition (ePI) identifier: National drug codes/0069-0688 (use: official, ) status: Active formOf: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] administrableDoseForm: Film Coated Tablet Dosage Form unitOfPresentation: Tablet Dosing Unit producedFrom: ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit property type: Structured Product Labeling Color value: Purple property type: Structured Product Labeling Shape value: Oval property type: SIZE value: 16 millimeter (Details: unitsofmeasure.org codemm = 'mm') property type: SPLIMPRINT value: Pfizer;PBC;125 routeOfAdministration code: Oral Route of Administration TargetSpecies - Code * Human
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0688
status:
  v: active
form of:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
administrable dose form:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C42931
    display:
      v: Film Coated Tablet Dosage Form
unit of presentation:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48542
    display:
      v: Tablet Dosing Unit
produced from:
  l: UUID-MID-PALBOCICLIB125
  reference:
    v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48556
      display:
        v: Structured Product Labeling Color
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48327
      display:
        v: Purple
property:
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48557
      display:
        v: Structured Product Labeling Shape
  value: CodeableConcept
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C48345
      display:
        v: Oval
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLSIZE
    text:
      v: SIZE
  value: Quantity
    value:
      v: 16
    unit:
      v: millimeter
    system:
      v: https://unitsofmeasure.org
      l: unitsofmeasure.org
    code:
      v: mm
property:
  type:
    coding:
      system:
        v: urn:oid:2.16.840.1.113883.1.11.19255
        l: 2.16.840.1.113883.1.11.19255
      code:
        v: SPLIMPRINT
  value: CodeableConcept
    text:
      v: Pfizer;PBC;125
route of administration:
  code:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C38288
      display:
        v: Oral Route of Administration

UUID-PPD-PALBOCICLIB75-TAB-MONTH
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB75-TAB-MONTH
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB75-TAB-MONTH Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC:0069-0284-03 (use: official, ) name: 75 MG TABLET DOSE PACK CARTON type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 3 in 1 CARTON MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC 0069-0284-03 type: Carton quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 3
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC:0069-0284-03
name:
  v: 75 MG TABLET DOSE PACK CARTON
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 3 in 1 CARTON
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC 0069-0284-03
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43182
      display:
        v: Carton
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB75
    amount:
      value:
        v: 3

UUID-PPD-PALBOCICLIB75-TAB-WEEK
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB75-TAB-WEEK
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB75-TAB-WEEK Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC 0069-0284-07 (use: official, ) name: 75 MG TABLET DOSE PACK type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 7 in 1 DOSE PACK; Type 0: Not a Combination Product MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC 0069-0284-07 type: Dose Pack quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 7
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC 0069-0284-07
name:
  v: 75 MG TABLET DOSE PACK
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 7 in 1 DOSE PACK; Type 0: Not a Combination Product
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC 0069-0284-07
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43192
      display:
        v: Dose Pack
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB75
    amount:
      value:
        v: 7

UUID-PPD-PALBOCICLIB100-TAB-MONTH
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB100-TAB-MONTH
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB100-TAB-MONTH Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC:0069-0486-03 (use: official, ) name: 100 MG TABLET DOSE PACK CARTON type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 3 in 1 CARTON MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC:0069-0486-03 type: Carton quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 3
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC:0069-0486-03
name:
  v: 100 MG TABLET DOSE PACK CARTON
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 3 in 1 CARTON
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC:0069-0486-03
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43182
      display:
        v: Carton
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB100
    amount:
      value:
        v: 3

UUID-PPD-PALBOCICLIB100-TAB-WEEK
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB100-TAB-WEEK
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB100-TAB-WEEK Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC:0069-0486-07 (use: official, ) name: 100 MG TABLET DOSE PACK type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 7 in 1 DOSE PACK; Type 0: Not a Combination Product MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC:0069-0486-07 type: Dose Pack quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Ireland Pharmaceuticals Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 7
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC:0069-0486-07
name:
  v: 100 MG TABLET DOSE PACK
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 7 in 1 DOSE PACK; Type 0: Not a Combination Product
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC:0069-0486-07
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43192
      display:
        v: Dose Pack
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG2
    reference:
      v: Organization/ORG2
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB100
    amount:
      value:
        v: 7

UUID-PPD-PALBOCICLIB125-TAB-MONTH
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB125-TAB-MONTH
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB125-TAB-MONTH Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC:0069-0688-03 (use: official, ) name: 125 MG TABLET DOSE PACK CARTON type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 3 in 1 CARTON MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC:0069-0688-03 type: Carton quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 3
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC:0069-0688-03
name:
  v: 125 MG TABLET DOSE PACK CARTON
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 3 in 1 CARTON
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC:0069-0688-03
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43182
      display:
        v: Carton
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB125
    amount:
      value:
        v: 3

UUID-PPD-PALBOCICLIB125-TAB-WEEK
type: PackagedProductDefinition
id:
  v: UUID-PPD-PALBOCICLIB125-TAB-WEEK
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi
    l: PackagedProductDefinition-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: PackagedProductDefinition UUID-PPD-PALBOCICLIB125-TAB-WEEK Profile: PackagedProductDefinition (ePI) identifier: National drug codes/NDC:0069-0688-07 (use: official, ) name: 125 MG TABLET DOSE PACK type: Drug Package packageFor: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] status: Active statusDate: 2020-03-30 00:00:00+0000 containedItemQuantity: 1 description: 7 in 1 DOSE PACK; Type 0: Not a Combination Product MarketingStatuses - Status * Marketing copackagedIndicator: false manufacturer: Organization Pfizer Manufacturing Deutschland GmbH packaging identifier: National drug codes/NDC:0069-0688-07 type: Dose Pack quantity: 1 ShelfLifeStorages - SpecialPrecautionsForStorage * Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack. manufacturer: Organization Pfizer Manufacturing Deutschland GmbH containedItem Items - Reference * ManufacturedItemDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); status = active; manufacturedDoseForm = Film Coated Tablet Dosage Form; unitOfPresentation = Tablet Dosing Unit amount: 7
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: NDC:0069-0688-07
name:
  v: 125 MG TABLET DOSE PACK
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C43233
    display:
      v: Drug Package
package for:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
status:
  coding:
    system:
      v: http://hl7.org/fhir/publication-status
      l: publication-status
    code:
      v: active
    display:
      v: Active
status date:
  v: 2020-03-30T00:00:00Z
contained item quantity:
  value:
    v: 1
description:
  v: 7 in 1 DOSE PACK; Type 0: Not a Combination Product
marketing status:
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C53292
      display:
        v: Marketing
copackaged indicator:
  v: false
manufacturer:
  l: ORG3
  reference:
    v: Organization/ORG3
packaging:
  identifier:
    system:
      v: http://hl7.org/fhir/sid/ndc
      l: ndc
    value:
      v: NDC:0069-0688-07
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C43192
      display:
        v: Dose Pack
  quantity:
    v: 1
  shelf life storage:
    special precautions for storage:
      text:
        v: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack.
  manufacturer:
    l: ORG3
    reference:
      v: Organization/ORG3
  contained item:
    item:
      reference:
        l: UUID-MID-PALBOCICLIB125
    amount:
      value:
        v: 7

UUID-RA-PALBOCICLIB75
type: RegulatedAuthorization
id:
  v: UUID-RA-PALBOCICLIB75
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization UUID-RA-PALBOCICLIB75 Profile: RegulatedAuthorization (ePI) identifier: National drug codes/0069-0284-03 (use: official, ) subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] type: Marketing Authorization description: Pfizer - NDC 0069-0284-03 - IBRANCE® (palbociclib) tablets - 75 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (75 mg per tablet). Rx only region: United States of America status: Approved for Human Use Product statusDate: 2020-03-30 00:00:00+0000 validityPeriod: 2020-11-01 00:00:00+0000 --> (ongoing) holder: Organization Pfizer Laboratories Div Pfizer Inc regulator: Organization Food and Drug Administration Cases - Identifier Type Status Date[x] * urn:oid:2.16.840.1.113883.3.150/NDA212436 NDA Approved for Human Use Product 2020-03-30 00:00:00+0000
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0284-03
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
description:
  v: Pfizer - NDC 0069-0284-03 - IBRANCE® (palbociclib) tablets - 75 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (75 mg per tablet). Rx only
region:
  coding:
    system:
      v: urn:iso:std:iso:3166
      l: 3166
    code:
      v: US
    display:
      v: United States of America
status:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
status date:
  v: 2020-03-30T00:00:00Z
validity period:
  start:
    v: 2020-11-01T00:00:00Z
holder:
  l: ORG1
  reference:
    v: Organization/ORG1
regulator:
  l: ORG5
  reference:
    v: Organization/ORG5
case:
  identifier:
    system:
      v: urn:oid:2.16.840.1.113883.3.150
      l: 2.16.840.1.113883.3.150
    value:
      v: NDA212436
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C73594
      display:
        v: Marketed under New Drug Application
    text:
      v: NDA
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C121840
      display:
        v: Approved for Human Use Product
  date: DateTime
    v: 2020-03-30T00:00:00Z

UUID-RA-PALBOCICLIB100-TAB-WEEK
type: RegulatedAuthorization
id:
  v: UUID-RA-PALBOCICLIB100-TAB-WEEK
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization UUID-RA-PALBOCICLIB100-TAB-WEEK Profile: RegulatedAuthorization (ePI) identifier: National drug codes/0069-0486-07 (use: official, ) subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] type: Marketing Authorization description: Pfizer - NDC 0069-0486-07 - IBRANCE® (palbociclib) tablets - 100 mg per tablet - This weekly pack contains: 7 tablets - Rx only region: United States of America status: Approved for Human Use Product statusDate: 2020-03-30 00:00:00+0000 validityPeriod: 2020-11-01 00:00:00+0000 --> (ongoing) holder: Organization Pfizer Laboratories Div Pfizer Inc regulator: Organization Food and Drug Administration Cases - Identifier Type Status Date[x] * urn:oid:2.16.840.1.113883.3.150/NDA212436 NDA Approved for Human Use Product 2020-03-30 00:00:00+0000
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0486-07
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
description:
  v: Pfizer - NDC 0069-0486-07 - IBRANCE® (palbociclib) tablets - 100 mg per tablet - This weekly pack contains: 7 tablets - Rx only
region:
  coding:
    system:
      v: urn:iso:std:iso:3166
      l: 3166
    code:
      v: US
    display:
      v: United States of America
status:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
status date:
  v: 2020-03-30T00:00:00Z
validity period:
  start:
    v: 2020-11-01T00:00:00Z
holder:
  l: ORG1
  reference:
    v: Organization/ORG1
regulator:
  l: ORG5
  reference:
    v: Organization/ORG5
case:
  identifier:
    system:
      v: urn:oid:2.16.840.1.113883.3.150
      l: 2.16.840.1.113883.3.150
    value:
      v: NDA212436
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C73594
      display:
        v: Marketed under New Drug Application
    text:
      v: NDA
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C121840
      display:
        v: Approved for Human Use Product
  date: DateTime
    v: 2020-03-30T00:00:00Z

UUID-RA-PALBOCICLIB125-TAB-MONTH
type: RegulatedAuthorization
id:
  v: UUID-RA-PALBOCICLIB125-TAB-MONTH
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization UUID-RA-PALBOCICLIB125-TAB-MONTH Profile: RegulatedAuthorization (ePI) identifier: National drug codes/0069-0688-03 (use: official, ) subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] type: Marketing Authorization description: Pfizer - NDC 0069-0688-03 - IBRANCE® (palbociclib) tablets - 125 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (125 mg per tablet). Rx only region: United States of America status: Approved for Human Use Product statusDate: 2020-03-30 00:00:00+0000 validityPeriod: 2020-11-01 00:00:00+0000 --> (ongoing) holder: Organization Pfizer Laboratories Div Pfizer Inc regulator: Organization Food and Drug Administration Cases - Identifier Type Status Date[x] * urn:oid:2.16.840.1.113883.3.150/NDA212436 NDA Approved for Human Use Product 2020-03-30 00:00:00+0000
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0688-03
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
description:
  v: Pfizer - NDC 0069-0688-03 - IBRANCE® (palbociclib) tablets - 125 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (125 mg per tablet). Rx only
region:
  coding:
    system:
      v: urn:iso:std:iso:3166
      l: 3166
    code:
      v: US
    display:
      v: United States of America
status:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
status date:
  v: 2020-03-30T00:00:00Z
validity period:
  start:
    v: 2020-11-01T00:00:00Z
holder:
  l: ORG1
  reference:
    v: Organization/ORG1
regulator:
  l: ORG5
  reference:
    v: Organization/ORG5
case:
  identifier:
    system:
      v: urn:oid:2.16.840.1.113883.3.150
      l: 2.16.840.1.113883.3.150
    value:
      v: NDA212436
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C73594
      display:
        v: Marketed under New Drug Application
    text:
      v: NDA
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C121840
      display:
        v: Approved for Human Use Product
  date: DateTime
    v: 2020-03-30T00:00:00Z

UUID-RA-PALBOCICLIB125
type: RegulatedAuthorization
id:
  v: UUID-RA-PALBOCICLIB125
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi
    l: RegulatedAuthorization-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: RegulatedAuthorization UUID-RA-PALBOCICLIB125 Profile: RegulatedAuthorization (ePI) identifier: National drug codes/0069-0688-07 (use: official, ) subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] type: Marketing Authorization description: Pfizer - NDC 0069-0688-07 - IBRANCE® (palbociclib) tablets - 125 mg per tablet - This weekly pack contains: 7 tablets - Rx only region: United States of America status: Approved for Human Use Product statusDate: 2020-03-30 00:00:00+0000 validityPeriod: 2020-11-01 00:00:00+0000 --> (ongoing) holder: Organization Pfizer Laboratories Div Pfizer Inc regulator: Organization Food and Drug Administration Cases - Identifier Type Status Date[x] * urn:oid:2.16.840.1.113883.3.150/NDA212436 NDA Approved for Human Use Product 2020-03-30 00:00:00+0000
identifier:
  use:
    v: official
  system:
    v: http://hl7.org/fhir/sid/ndc
    l: ndc
  value:
    v: 0069-0688-07
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C156642
    display:
      v: Marketing Authorization
description:
  v: Pfizer - NDC 0069-0688-07 - IBRANCE® (palbociclib) tablets - 125 mg per tablet - This weekly pack contains: 7 tablets - Rx only
region:
  coding:
    system:
      v: urn:iso:std:iso:3166
      l: 3166
    code:
      v: US
    display:
      v: United States of America
status:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C121840
    display:
      v: Approved for Human Use Product
status date:
  v: 2020-03-30T00:00:00Z
validity period:
  start:
    v: 2020-11-01T00:00:00Z
holder:
  l: ORG1
  reference:
    v: Organization/ORG1
regulator:
  l: ORG5
  reference:
    v: Organization/ORG5
case:
  identifier:
    system:
      v: urn:oid:2.16.840.1.113883.3.150
      l: 2.16.840.1.113883.3.150
    value:
      v: NDA212436
  type:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C73594
      display:
        v: Marketed under New Drug Application
    text:
      v: NDA
  status:
    coding:
      system:
        v: http://ncit.nci.nih.gov
        l: ncit.nci.nih.gov
      code:
        v: C121840
      display:
        v: Approved for Human Use Product
  date: DateTime
    v: 2020-03-30T00:00:00Z

interaction-carbamazepine
type: ClinicalUseDefinition
id:
  v: interaction-carbamazepine-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-carbamazepine-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/N40HCS9740 (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Carbamazepine
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: N40HCS9740
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-enzalutamide
type: ClinicalUseDefinition
id:
  v: interaction-enzalutamide-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-enzalutamide-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/4S9YUX2YRV (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Enzalutamide
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 4S9YUX2YRV
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-stjohnswort
type: ClinicalUseDefinition
id:
  v: interaction-stjohnswort-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-stjohnswort-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/G2M3PPT97G (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * St John’s Wort
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: G2M3PPT97G
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-alfentanil
type: ClinicalUseDefinition
id:
  v: interaction-alfentanil-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-alfentanil-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/1HCV40FHJT (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Alfentanil
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 1HCV40FHJT
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-cyclosporine
type: ClinicalUseDefinition
id:
  v: interaction-cyclosporine-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-cyclosporine-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/83HN0GTJ6D (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Cyclosporine
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 83HN0GTJ6D
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-dihydroergotamine
type: ClinicalUseDefinition
id:
  v: interaction-dihydroergotamine-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-dihydroergotamine-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/4L4Z42S42Y (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Dihydroergotamine
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 4L4Z42S42Y
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-ergotamine
type: ClinicalUseDefinition
id:
  v: interaction-ergotamine-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-ergotamine-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/LH5S7Z74VZ (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Ergotamine
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: LH5S7Z74VZ
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-everolimus
type: ClinicalUseDefinition
id:
  v: interaction-everolimus-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-everolimus-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/8J18F9030N (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Everolimus
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 8J18F9030N
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-fentanyl
type: ClinicalUseDefinition
id:
  v: interaction-fentanyl-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-fentanyl-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/AN3HR2L44E (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Fentanyl
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: AN3HR2L44E
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-pimozide
type: ClinicalUseDefinition
id:
  v: interaction-pimozide-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-pimozide-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/HOP0PPN3MB (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Pimozide
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: HOP0PPN3MB
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-quinidine
type: ClinicalUseDefinition
id:
  v: interaction-quinidine-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-quinidine-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/2J18XH63HH (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Quinidine
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: 2J18XH63HH
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-sirolimus
type: ClinicalUseDefinition
id:
  v: interaction-sirolimus-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-sirolimus-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/W36ZG6FT64 (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Sirolimus
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: W36ZG6FT64
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

interaction-tacrolimus
type: ClinicalUseDefinition
id:
  v: interaction-tacrolimus-id
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi
    l: ClinicalUseDefinition-interaction-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition interaction-tacrolimus-id Profile: ClinicalUseDefinition Interaction (ePI) identifier: https://gsrs.ncats.nih.gov/ginas/app/beta/Y5L2157C4J (use: official, ) type: Interaction subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] interaction Interactants - Item[x] * Tacrolimus
identifier:
  use:
    v: official
  system:
    v: https://gsrs.ncats.nih.gov/ginas/app/beta
    l: beta
  value:
    v: Y5L2157C4J
type:
  v: interaction
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125
interaction:
  interactant:
    item: CodeableConcept

indication-hrposher2
type: ClinicalUseDefinition
id:
  v: indication-hrposher2
meta:
  profile:
    v: http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-indication-uv-epi
    l: ClinicalUseDefinition-indication-uv-epi
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition indication-hrposher2 Profile: ClinicalUseDefinition Indication (ePI) identifier: http://example.org/sid/767444009 type: Indication subject: MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0284 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0486 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] MedicinalProductDefinition: identifier = http://hl7.org/fhir/sid/ndc#National drug codes#0069-0688 (use: official, ); type = Approved for Human Use Product; domain = Human; version = 1; status = Active; statusDate = 2020-03-30 00:00:00+0000; combinedPharmaceuticalDoseForm = Film Coated Tablet Dosage Form; legalStatusOfSupply = Marketing Authorization; classification = Kinase Inhibitor [EPC] indication DiseaseSymptomProcedures - Concept * Germline BRCA-mutated human epidermal growth factor receptor 2 negative metastatic carcinoma of breast (disorder)
identifier:
  system:
    v: http://example.org/sid
    l: sid
  value:
    v: 767444009
type:
  v: indication
subject:
  l: UUID-MPD-PALBOCICLIB75
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB75
subject:
  l: UUID-MPD-PALBOCICLIB100
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB100
subject:
  l: UUID-MPD-PALBOCICLIB125
  reference:
    v: MedicinalProductDefinition/UUID-MPD-PALBOCICLIB125

full url:
  v: RegulatedAuthorization/UUID-RA-PALBOCICLIB100-TAB-WEEK
  l: UUID-RA-PALBOCICLIB100-TAB-WEEK
resource: UUID-RA-PALBOCICLIB100-TAB-WEEK

full url:
  v: RegulatedAuthorization/UUID-RA-PALBOCICLIB125-TAB-MONTH
  l: UUID-RA-PALBOCICLIB125-TAB-MONTH
resource: UUID-RA-PALBOCICLIB125-TAB-MONTH

full url:
  v: RegulatedAuthorization/UUID-RA-PALBOCICLIB125
  l: UUID-RA-PALBOCICLIB125
resource: UUID-RA-PALBOCICLIB125

full url:
  v: ClinicalUseDefinition/interaction-carbamazepine
  l: interaction-carbamazepine
resource: interaction-carbamazepine

full url:
  v: ClinicalUseDefinition/interaction-enzalutamide
  l: interaction-enzalutamide
resource: interaction-enzalutamide

full url:
  v: ClinicalUseDefinition/interaction-stjohnswort
  l: interaction-stjohnswort
resource: interaction-stjohnswort

full url:
  v: ClinicalUseDefinition/interaction-alfentanil
  l: interaction-alfentanil
resource: interaction-alfentanil

full url:
  v: ClinicalUseDefinition/interaction-cyclosporine
  l: interaction-cyclosporine
resource: interaction-cyclosporine

full url:
  v: ClinicalUseDefinition/interaction-dihydroergotamine
  l: interaction-dihydroergotamine
resource: interaction-dihydroergotamine

full url:
  v: ClinicalUseDefinition/interaction-ergotamine
  l: interaction-ergotamine
resource: interaction-ergotamine

full url:
  v: ClinicalUseDefinition/interaction-everolimus
  l: interaction-everolimus
resource: interaction-everolimus

full url:
  v: ClinicalUseDefinition/interaction-fentanyl
  l: interaction-fentanyl
resource: interaction-fentanyl

full url:
  v: ClinicalUseDefinition/interaction-pimozide
  l: interaction-pimozide
resource: interaction-pimozide

full url:
  v: ClinicalUseDefinition/interaction-quinidine
  l: interaction-quinidine
resource: interaction-quinidine

full url:
  v: ClinicalUseDefinition/interaction-sirolimus
  l: interaction-sirolimus
resource: interaction-sirolimus

full url:
  v: ClinicalUseDefinition/interaction-tacrolimus
  l: interaction-tacrolimus
resource: interaction-tacrolimus

full url:
  v: ClinicalUseDefinition/indication-hrposher2
  l: indication-hrposher2
resource: indication-hrposher2

v: 42229-5

v: SPL UNCLASSIFIED SECTION

v: 42229-5

v: SPL UNCLASSIFIED SECTION

id:
  v: UUID-NESTED-SECTION-3
title:
  v: What is IBRANCE?
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  id:
    v: UUID-NESTED-SECTION-3-TEXT
  status:
    v: generated
  div:
    v: IBRANCE is a prescription medicine used in adults to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with: an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or fulvestrant in people with disease progression following hormonal therapy. It is not known if IBRANCE is safe and effective in children.

id:
  v: UUID-NESTED-SECTION-4
title:
  v: Before taking IBRANCE, tell your healthcare provider about all of your medical conditions, including if you:
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: have fever, chills, or any other signs or symptoms of infection. have liver or kidney problems. are pregnant, or plan to become pregnant. IBRANCE can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your healthcare provider may ask you to take a pregnancy test before you start treatment with IBRANCE. Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE. Talk to your healthcare provider about birth control methods that may be right for you during this time. If you become pregnant or think you are pregnant, tell your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other causing side effects.

id:
  v: UUID-NESTED-SECTION-5
title:
  v: How should I take IBRANCE?
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Take IBRANCE exactly as your healthcare provider tells you. IBRANCE tablets may be taken with or without food. IBRANCE should be taken at about the same time each day. Swallow IBRANCE tablets whole. Do not chew, crush or split IBRANCE tablets before swallowing them. Do not take any IBRANCE tablets that are broken, cracked, or that look damaged. Avoid grapefruit and grapefruit products during treatment with IBRANCE. Grapefruit may increase the amount of IBRANCE in your blood. Do not change your dose or stop taking IBRANCE unless your healthcare provider tells you. If you miss a dose of IBRANCE or vomit after taking a dose of IBRANCE, do not take another dose on that day. Take your next dose at your regular time. If you take too much IBRANCE, call your healthcare provider right away or go to the nearest hospital emergency room.

id:
  v: UUID-NESTED-SECTION-6
title:
  v: What are the possible side effects of IBRANCE?
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: IBRANCE may cause serious side effects. See "What is the most important information I should know about IBRANCE?" The most common side effects of IBRANCE when used with either letrozole or fulvestrant include: Low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare provider right away if you develop any of these symptoms during treatment: dizziness shortness of breath weakness bleeding or bruising more easily nosebleeds infections (see "What is the most important information I should know about IBRANCE? ") tiredness nausea sore mouth abnormalities in liver blood tests diarrhea hair thinning or hair loss vomiting rash loss of appetite IBRANCE may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider about family planning options before starting IBRANCE if this is a concern for you. These are not all of the possible side effects of IBRANCE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

id:
  v: UUID-NESTED-SECTION-7
title:
  v: How should I store IBRANCE?
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Store IBRANCE at 68 °F to 77 °F (20 °C to 25 °C) in the original blister pack. Keep IBRANCE and all medicines out of the reach of children.

id:
  v: UUID-NESTED-SECTION-8
title:
  v: General information about the safe and effective use of IBRANCE
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IBRANCE for a condition for which it was not prescribed. Do not give IBRANCE to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about IBRANCE that is written for health professionals.

id:
  v: UUID-NESTED-SECTION-9
title:
  v: What are the ingredients in IBRANCE?
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Active ingredient: palbociclib Inactive ingredients: microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, succinic acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and FD&C Blue #2/Indigo Carmine Aluminum Lake. In addition, the 75 mg and 125 mg tablets contain red iron oxide and the 100 mg tablets contain yellow iron oxide. LAB-1372-1.0 For more information, go to www.IBRANCE.com or call 1-800-438-1985.

id:
  v: UUID-NESTED-SECTION-10
title:
  v: PRINCIPAL DISPLAY PANEL - TOPPER CARD
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Your Monthly Box Includes 3 weekly packs of IBRANCE® (palbociclib) medication. Fill in the dates below to help track your treatment cycle. Treatment Cycle Week 1 Week 2 Week 3 IBRANCE Week 4 No IBRANCE My Treatment Cycle Tracker I start my Week 1 treatment cycle on: ________ / ______ MONTH DAY After Week 4, I will start my next treatment cycle on: ________ / ______ MONTH DAY PAA119239

id:
  v: UUID-NESTED-SECTION-11
title:
  v: PRINCIPAL DISPLAY PANEL - 75 MG TABLET DOSE PACK
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0284-07 IBRANCE® (palbociclib) tablets 75 mg per tablet This weekly pack contains: 7 tablets Rx only

id:
  v: UUID-NESTED-SECTION-12
title:
  v: PRINCIPAL DISPLAY PANEL - 75 MG TABLET DOSE PACK CARTON
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0284-03 IBRANCE® (palbociclib) tablets 75 mg 21 tablets Monthly Box Contains: 3 individual weekly packs. Each pack contains 7 IBRANCE tablets (75 mg per tablet). Rx only Safety Label

id:
  v: UUID-NESTED-SECTION-13
title:
  v: PRINCIPAL DISPLAY PANEL - 100 MG TABLET DOSE PACK
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0486-07 IBRANCE® (palbociclib) tablets 100 mg per tablet This weekly pack contains: 7 tablets Rx only

id:
  v: UUID-NESTED-SECTION-14
title:
  v: PRINCIPAL DISPLAY PANEL - 100 MG TABLET DOSE PACK CARTON
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0486-03 IBRANCE® (palbociclib) tablets 100 mg 21 tablets Monthly Box Contains: 3 individual weekly packs. Each pack contains 7 IBRANCE tablets (100 mg per tablet). Rx only Safety Label

id:
  v: UUID-NESTED-SECTION-15
title:
  v: PRINCIPAL DISPLAY PANEL - 125 MG TABLET DOSE PACK
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0688-07 IBRANCE® (palbociclib) tablets 125 mg per tablet This weekly pack contains: 7 tablets Rx only

id:
  v: UUID-NESTED-SECTION-16
title:
  v: PRINCIPAL DISPLAY PANEL - 125 MG TABLET DOSE PACK CARTON
code:
  coding: https://loinc.org/rdf/42229-5
    system:
      v: http://loinc.org
      l: loinc.org
    code:
      v: 42229-5
    display:
      v: SPL UNCLASSIFIED SECTION
text:
  status:
    v: generated
  div:
    v: Pfizer NDC 0069-0688-03 IBRANCE® (palbociclib) tablets 125 mg 21 tablets Monthly Box Contains: 3 individual weekly packs. Each pack contains 7 IBRANCE tablets (125 mg per tablet). Rx only Safety Label

v: 2S7830E561

v: CROSPOVIDONE

v: L06K8R7DQK

v: FD&C BLUE NO. 2

v: 1K09F3G675

v: FERRIC OXIDE RED

v: EX438O2MRT

v: FERRIC OXIDE YELLOW

v: 0WZ8WG20P6

v: HYPROMELLOSE 2910 (6 MPA.S)

v: 70097M6I30

v: MAGNESIUM STEARATE

v: OP1R32D61U

v: MICROCRYSTALLINE CELLULOSE

v: G9ZF61LE7G

v: 75

v: mg

v: 1

v: 1

v: G9ZF61LE7G

v: 100

v: mg

v: 1

v: 1

v: G9ZF61LE7G

v: 125

v: mg

v: 1

v: 1

v: ETJ7Z6XBU4

v: SILICON DIOXIDE

v: AB6MNQ6J6L

v: SUCCINIC ACID

v: 15FIX9V2JP

v: 15FIX9V2JP

v: XHX3C3X673

v: TRIACETIN

v: C48329

v: Green

v: GREEN

type:
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48557
    display:
      v: Structured Product Labeling Shape
  text:
    v: SHAPE
value: CodeableConcept
  coding:
    system:
      v: http://ncit.nci.nih.gov
      l: ncit.nci.nih.gov
    code:
      v: C48345
    display:
      v: Oval
  text:
    v: OVAL

type:
  coding:
    system:
      v: urn:oid:2.16.840.1.113883.1.11.19255
      l: 2.16.840.1.113883.1.11.19255
    code:
      v: SPLSIZE
  text:
    v: SIZE
value: Quantity
  value:
    v: 15
  unit:
    v: millimeter
  system:
    v: https://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: mm

type:
  coding:
    system:
      v: urn:oid:2.16.840.1.113883.1.11.19255
      l: 2.16.840.1.113883.1.11.19255
    code:
      v: SPLIMPRINT
value: CodeableConcept
  text:
    v: Pfizer;PBC;100

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:639
l: 639

v: EN

v: English

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:639
l: 639

v: EN

v: English

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:3166
l: 3166

v: US

v: United States of America

v: urn:iso:std:iso:639
l: 639

v: EN

v: English

v: C14225

v: Human

v: C14225

v: Human

v: C14225

v: Human

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB75

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB100

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125

v: C101707

v: Recommended Storage Temperature

v: ManufacturedItemDefinition/UUID-MID-PALBOCICLIB125

v: N40HCS9740

v: Carbamazepine

v: 4S9YUX2YRV

v: Enzalutamide

v: G2M3PPT97G

v: St John’s Wort

v: 1HCV40FHJT

v: Alfentanil

v: 83HN0GTJ6D

v: Cyclosporine

v: 4L4Z42S42Y

v: Dihydroergotamine

v: LH5S7Z74VZ

v: Ergotamine

v: 8J18F9030N

v: Everolimus

v: AN3HR2L44E

v: Fentanyl

v: HOP0PPN3MB

v: Pimozide

v: 2J18XH63HH

v: Quinidine

v: W36ZG6FT64

v: Sirolimus

v: Y5L2157C4J

v: Tacrolimus

v: 767444009

v: Germline BRCA-mutated human epidermal growth factor receptor 2 negative metastatic carcinoma of breast (disorder)